InvestorsHub Logo
Post# of 15261
Next 10
Followers 3
Posts 617
Boards Moderated 0
Alias Born 07/26/2006

Re: None

Thursday, 05/31/2007 1:28:34 PM

Thursday, May 31, 2007 1:28:34 PM

Post# of 15261
Hi Tsafi, ACTC had some interesting news today, think it might start to turn here:

ACTC (.67) Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure

The letter of intent provides for an aggregate purchase price of $5 million payable in ACTC common stock plus the assumption of certain Mytogen liabilities of approximately $1 million. Mytogen will also receive a warrant to purchase an additional 1.5 million shares of ACTC common stock at $1.00 subject to achievement of certain milestones. The letter of intent is subject to several closing conditions including requisite approvals from the Food and Drug Administration (FDA), final intellectual property due diligence and execution of a definitive agreement. The transaction is scheduled to close by July 15, 2007. Upon completion of the acquisition, Advanced Cell Technology will transition from a development stage to a clinical stage company. Mytogen brings to the Company over ten years of experience in clinical trial and FDA experience in developing and advancing cellular therapies including the area of stem cells.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.